沙库巴曲缬沙坦治疗慢性心力衰竭患者疗效及肝肾功能影响

摘要/Abstract

摘要： 目的观察沙库巴曲缬沙坦治疗慢性心力衰竭患者疗效及对肝肾功能的影响。方法选取2021年1月—2021年12月在陕西省铜川市人民医院就诊或住院的慢性心力衰竭患者200例作为研究对象,按照随机数表法分为观察组和对照组,每组100例,对照组给予利尿剂、扩张血管药物、β-受体拮抗剂等治疗,观察组在对照组基础上给予沙库巴曲缬沙坦治疗,对比两组患者治疗总有效率、治疗前后肝肾功能、心功能及治疗后不良反应发生率。结果观察组患者的治疗总有效率高于对照组（P<0.05）;治疗前两组患者的谷氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、血清肌酐（Scr）、尿素氮（BUN）水平比较,差异无统计学意义（P>0.05）,治疗后两组患者的ALT、AST、SCr、BUN水平均降低,并且治疗后观察组患者以上指标明显低于对照组（P<0.05）;治疗前两组患者的N-末端B型利钠肽原（NT-proBNP）水平比较,差异无统计学意义（P>0.05）,治疗后两组患者的NT-proBNP水平均降低,并且治疗后观察组患者NT-proBNP水平明显低于对照组（P<0.05）;治疗前两组患者的左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左心室射血分数（LVEF）、6 min步行试验（6MWT）水平比较,差异无统计学意义（P>0.05）,治疗后两组患者的LVEDD、LVESD水平均降低,LVEF、6MWT水平均升高,并且观察组患者以上指标改善情况优于对照组（P<0.05）;两组患者不良反应发生率比较,差异无统计学意义（P>0.05）。结论给予慢性心力衰竭患者沙库巴曲缬沙坦治疗,能提升治疗效果,促进肝肾功能、心功能改善,延缓病情进展,且不会增加不良反应。

关键词: 沙库巴曲缬沙坦, 慢性心力衰竭, 疗效, 肝肾功能

Abstract: Objective To observe the effect and influence of liver and kidney function of Sacubitril Valsartan in patients of chronic heart failure. Methods 200 patients with chronic heart failure who were treated or hospitalized in Tongchuan People's Hospital from January 2021 to December 2021 were collected as the subjects of this study. According to the method of random number table, they were divided into observation group and control group, 100 patients in each group, both groups were given diuretics, vasodilators, β-Receptor antagonists and other treatments. The observation group was treated with Sacubitril Valsartan on the basis of the above. The total effective rate, the liver and kidney functions and cardiac functions before and after treatment, and the incidence of adverse reactions after treatment of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group (P<0.05); there was no significant difference in Alt, AST, SCR and BUN levels between the two groups before treatment (P>0.05), after treatment, the Alt, AST, SCR and BUN levels of the two groups were decreased, and after treatment, the above indexes of the observation group were decreased, the range was greater than that of the control group (P<0.05); there was no significant difference in NT-proBNP levels between the two groups before treatment (P>0.05), after treatment, NT-proBNP levels in the two groups decreased on average, and after treatment, the decrease in the observation group was greater than that in the control group (P<0.05); there was no significant difference in the levels of LVEDD, LVESD, LVEF and 6MWT between the two groups before treatment (P>0.05), after treatment, the levels of LVEDD and LVESD in the two groups decreased, and the levels of LVEF and 6MWT increased on average, the improvement of the above indexes in the observation group was better than that in the control group (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of chronic heart failure patients with Sacubitril Valsartan can improve the treatment effect, promote the improvement of liver, kidney function and heart function, delay the progress of the disease, and it will not increase the adverse reactions.

Key words: sacubitril valsartan, chronic heart failure, curative effect, liver and kidney function

中图分类号:

R541

闫伟, 杨小兰, 杨浩, 康莉平, 张润梅, 李文娟, 惠星伟. 沙库巴曲缬沙坦治疗慢性心力衰竭患者疗效及肝肾功能影响[J]. 中华养生保健, 2023, 41(6): 8-11.

YAN Wei, YANG Xiao-lan, YANG Hao, KANG Li-ping, ZHANG Run-mei, LI Wen-juan, HUI Xing-wei. The Effect of Sacubitril Valsartan on Liver and Kidney Function in Patients with Chronic Heart Failure[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(6): 8-11.

参考文献 11

[1]	李江,刘文娴,赵晗,等.沙库巴曲缬沙坦治疗老年人扩张型心肌病致慢性心力衰竭的疗效观察[J].中国医药,2021,16(6):485-488.
[2]	华伟,顾敏,宿燕岗,等.中国慢性心力衰竭患者中左心室多位点起搏有效性和安全性的观察和评价[J].中华心律失常学杂志,2022,26(2): 152-158.
[3]	孔祥栋,许金华,齐玲,等.沙库巴曲缬沙坦钠治疗维持性血液透析合并慢性心力衰竭的疗效及对血清炎症因子水平的影响[J].中国中西医结合肾病杂志,2022,23(3):252-254.
[4]	范婷婷,何非,王晓晨.沙库巴曲缬沙坦与缬沙坦治疗慢性心力衰竭的早期临床疗效比较[J].安徽医学,2019,40(6):21-24.
[5]	程明月,张辉,徐晤,等.沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的疗效研究[J].现代生物医学进展,2019,19(22):4295-4298.
[6]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[7]	张瑜,李利华.慢性心力衰竭患者及其主要照顾者心力衰竭相关知识现状及影响因素研究[J].实用心脑肺血管病杂志,2020,28(11):83-90.
[8]	张磊,丁辉.通心络胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的疗效及对患者心功能和炎症因子的影响[J].海南医学,2021,32(24):3162-3165.
[9]	郑冠群,盛晓东,周建龙,等.沙库巴曲/缬沙坦治疗射血分数降低的慢性心力衰竭的效果及对神经内分泌激素活性和粒淋比的影响[J].中国循证心血管医学杂志,2021,13(11):1346-1349
[10]	张苒,李彬,李娜.沙库巴曲缬沙坦对扩张型心肌病并发慢性心力衰竭患者治疗效果及炎性因子的影响[J].临床误诊误治,2021, 34(6):39-43.
[11]	桑海强,马振周,江耀辉,等.沙库巴曲缬沙坦治疗中国射血分数降低心力衰竭患者的药物经济学评价[J].中国临床药理学杂志,2022, 38(7):722-726.

[1]	孙涛, 蔡珂, 刘姿杉, 周春丽, 孙龙军. 金丹排石汤治疗湿热型输尿管结石的临床效果[J]. 中华养生保健, 2024, 42(9): 12-16.
[2]	张立伟, 王颖, 李懿娇, 徐金婵. 埋针联合耳穴压豆辅助治疗慢阻肺疾病痰浊阻肺证患者的疗效观察[J]. 中华养生保健, 2024, 42(9): 21-24.
[3]	刘燕, 侯聪. 血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭患者的应用效果及对神经内分泌因子的影响[J]. 中华养生保健, 2024, 42(9): 28-31.
[4]	覃桂水, 陶怡, 郑美华. “以通为用”指导下不同刮痧方法在气滞血瘀型肩周炎患者中的临床应用[J]. 中华养生保健, 2024, 42(9): 31-34.
[5]	李伟. 中医药透配合针灸治疗老年性膝关节骨性关节炎的临床观察[J]. 中华养生保健, 2024, 42(9): 34-37.
[6]	杨楠. 滋阴清热汤治疗月经不调的临床疗效及对血清激素水平的影响研究[J]. 中华养生保健, 2024, 42(9): 37-39.
[7]	王苑. BNP联合cTnT对UAP合并CHF的诊断及术后不良心血管事件的预测[J]. 中华养生保健, 2024, 42(9): 48-52.
[8]	孙欢欢. 依达拉奉联合阿托伐他汀治疗脑梗死恢复期患者的相关研究[J]. 中华养生保健, 2024, 42(9): 187-190.
[9]	李晓琳, 李斯文, 冯妮. 四君子汤联合替吉奥治疗晚期胃癌患者的临床疗效及安全性分析[J]. 中华养生保健, 2024, 42(8): 24-27.
[10]	喻霞, 齐慧丽, 张春红. 紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响[J]. 中华养生保健, 2024, 42(8): 40-44.
[11]	云佳. 慢性心力衰竭合并房颤者应用心理护理效果研究[J]. 中华养生保健, 2024, 42(8): 100-103.
[12]	马周宇. 非锁定钢板内固定术和锁定钢板内固定术治疗跟骨粉碎性骨折的临床效果比较研究[J]. 中华养生保健, 2024, 42(8): 174-177.
[13]	杨廷智, 马平, 付有娟, 罗兵, 何文清. 敷膝热奄包联合推拿治疗膝关节炎的临床疗效观察[J]. 中华养生保健, 2024, 42(7): 1-4.
[14]	邵光辉. 云南白药胶囊辅助经皮微创内固定术对胫骨平台骨折患者愈合的影响[J]. 中华养生保健, 2024, 42(7): 23-26.
[15]	闵晶晶, 杜林栋, 聂成梅. 益肾扶阳粉隔药灸法对肾病综合征水肿的治疗效果观察[J]. 中华养生保健, 2024, 42(6): 1-4.